Valuation: Lakefront Biotherapeutics NV

Market Cap 2.01B 2.22B 1.86B 1.68B 3.17B 207B 3.29B 22.42B 8.87B 112B 8.32B 8.15B 353B P/E 2026 *
-12.3x
P/E 2027 * -9.32x
Enterprise Value -27.82M -30.65M -25.7M -23.19M -43.77M -2.86B -45.45M -310M -122M -1.55B -115M -113M -4.88B EV / Sales 2026 *
-0.77x
EV / Sales 2027 * 5.84x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
1 day+0.77%
1 week+5.36%
Current month+8.78%
1 month+19.53%
3 months+31.63%
6 months+34.44%
Current year+12.36%
1 week 29.4
Extreme 29.4
32.08
1 month 26.16
Extreme 26.16
32.08
Current year 22.32
Extreme 22.32
32.08
1 year 22.32
Extreme 22.32
32.08
3 years 20
Extreme 20
39
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap. Importance
1/28/26 Buy

Director

137 0.0002%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
+0.77%+5.36%+15.24%-8.23% 2.2B
+1.15%-2.81%+55.79%+71.12% 65.56B
-2.64%+0.07%+9.57%+89.87% 60.41B
-1.07%+0.55%+21.79%+87.66% 55.76B
+0.48%-2.53%+9.73%+121.14% 46.98B
-2.69%-6.38%+19.19%+25.79% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.50%-15.73%+135.31%+662.73% 36.09B
-0.77%-4.34%+79.27%+59.47% 32.9B
-0.83%+1.98%-38.27%+390.98% 26.96B
Average -0.88%-1.21%+32.17%+154.57% 41B
Weighted average by Cap. -0.98%-1.59%+33.78%+146.99%

Financials

2026 *2027 *
Net sales 36.35M 40.05M 33.58M 30.3M 57.19M 3.74B 59.38M 405M 160M 2.02B 150M 147M 6.38B 83.92M 92.44M 77.52M 69.94M 132M 8.64B 137M 934M 369M 4.66B 347M 340M 14.73B
Net income -67.69M -74.56M -62.53M -56.41M -106M -6.97B -111M -753M -298M -3.76B -280M -274M -11.88B -183M -201M -169M -152M -288M -18.82B -299M -2.04B -805M -10.16B -756M -740M -32.09B
Net Debt -2.04B -2.25B -1.89B -1.7B -3.21B -210B -3.34B -22.73B -8.99B -113B -8.44B -8.26B -358B -1.52B -1.68B -1.41B -1.27B -2.4B -157B -2.49B -16.97B -6.71B -84.66B -6.3B -6.17B -267B
Projected Income Statement - Annual - Lakefront Biotherapeutics NV
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
196
Date Price Change Volume
26-11-17 €31.46 +0.77% 120,670
26-11-16 €31.22 +3.45% 114,956
26-11-13 €30.18 -2.77% 63,827
26-11-12 €31.04 +4.16% 178,853
26-11-11 €29.80 +1.09% 66,952
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Lakefront Biotherapeutics NV
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
31.46EUR
Average target price
32.61EUR
Spread / Average Target
+3.67%
  1. Stock Market
  2. Stocks
  3. LKFT Stock